title: Beleodaq approved for rare lymphomas.
abstract: On July 3, the FDA granted accelerated approval to Beleodaq, a histone deacetylase inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017277:Drug Approval; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D008223:Lymphoma / Q000188:drug therapy*; D013449:Sulfonamides / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D013449:Sulfonamides; C487081:belinostat